Simotinib
Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 19.9 nM. Antineoplastic activities[1].
Product Specifications
CAS Number
944258-89-3
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/simotinib.html
Purity
99.39
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COC1=CC2=C(C(NC(C=C3)=CC(Cl)=C3F)=NC=N2)C=C1OCCN4CC5(CC5)C6(OCCO6)C4
Molecular Formula
C25H26ClFN4O4
Molecular Weight
500.95
References & Citations
[1]Hu XS, et al. Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial. Cancer Manag Res. 2019;11:4449-4459. Published 2019 May 13.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
EGFR/ErbB1/HER1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
